An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults.

×

Message d'erreur

  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 53 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
  • Notice : Trying to access array offset on value of type null dans bootstrap_pager() (ligne 95 dans /var/www/biosafety.be/sites/all/themes/bootstrap/templates/system/pager.func.php).
Study title: 
An open-label, phase I, dose-escalation and safety study of two intramuscular injections at dose of 2.9 log or 4 log CCID50 of the recombinant HIV I clade B measles vaccine vector in healthy adults.
Date receipt dossier: 
8 juil 2010
Company / Sponsor: 
Institut Pasteur - Paris
Phase: 
I
Treated organism: 
Humans
Indication category: 
Infectious disease
Disease: 
AIDS
Therapeutic approach: 
Immunotherapy
Genetic modification: 
Gag, Pol, Nef genes of HIV
Method of transfer of nucleic acid of interest: 
Attenuated measles virus Schwarz strain
Administered biological material: 
Recombinant attenuated measles virus
Route of administration: 
Intramuscular
Locations in Belgium: 
UZ Gent
Type of procedure: 
Contained use only
Current status: 
Authorized